Clinical Trial Detail

NCT ID NCT03912064
Title A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

acute myeloid leukemia

myelofibrosis

myelodysplastic syndrome

chronic myelomonocytic leukemia

myelodysplastic/myeloproliferative neoplasm

Therapies

Ipilimumab

Age Groups: adult senior

No variant requirements are available.